Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

14 Sep 2007 08:55

Phytopharm PLC14 September 2007 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1. (1) An issuer making a notification in respect of a transaction relating toshares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating tothe shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrumentrelating to the shares of the issuer (other than a debenture) should completeboxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or PHYTOPHARM PLC (ii) DR 3.1.4R(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) NOTIFICATION RELATES TO (iii) 3. Name of person discharging 4. State whether notification managerial responsibilities/ relates to a person connected director with a person discharging managerial responsibilities/ director named in 3 and identify the connected person DR DARYL REES AS 3 ABOVE 5. Indicate whether the notification 6. Description of shares (including is in respect of a holding of the class), debentures or derivatives person referred to in 3 or 4 or in or financial instruments relating respect of a non-beneficial to shares interest AS 3 ABOVE OPTIONS OVER ORDINARY SHARES OF 1 PENCE EACH 7. Name of registered shareholder(s) 8. State the nature of the and, if more than one, the number transaction of shares held by each of them GRANT OF AN SAYE SHARE OPTION UNDER THE PHYTOPHARM SHARESAVE PLAN 2007 9. Number of shares, debentures or 10. Percentage of issued class financial instruments relating to acquired (treasury shares of that shares acquired class should not be taken into account when calculating percentage) 11. Number of shares, debentures or 12. Percentage of issued class financial instruments relating to disposed (treasury shares of that shares disposed class should not be taken into account when calculating percentage) 13. Price per share or value of 14. Date and place of transaction transaction 15. Total holding following 16. Date issuer informed of notification and total percentage transaction holding following notification (treasury shares of that class should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised 12 SEPTEMBER 2007 1 OCTOBER 2010 TO 31 MARCH 2011 19. Total amount paid (if any) for grant 20. Description of shares or of the option debentures involved (class and number) NIL 19,585 PHYTOHARM PLC ORDINARY 1 PENCE SHARES 21. Exercise price (if fixed at the time 22. Total number of shares or of grant) or indication that price is debentures over which options to be fixed at the time of exercise held following notification EXERCISE PRICE FORTY EIGHT AND ONE 1,278,559 QUARTER PENCE PER SHARE 23. Any additional information 24. Name of contact and telephone number for queries ZOE MCGOWAN 01480 437697 Name and signature of duly authorised officer of issuer responsible for makingnotification------------------------------------------------___ZOE MCGOWAN_________________________________________________________ Date of notification _14 SEPTEMBER 2007____________________________________ ------------------------------------------------ This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Aug 20195:38 pmRNSDirector/PDMR Shareholding
19th Aug 20194:40 pmRNSSecond Price Monitoring Extn
19th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSTrading Update
9th Aug 20197:00 amRNSIXICO provides update on new & current contracts
23rd Jul 201911:05 amRNSSecond Price Monitoring Extn
23rd Jul 201911:00 amRNSPrice Monitoring Extension
11th Jul 20197:00 amRNSDirector and PDMR share purchase
10th Jun 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHalf Yearly Report to 31 March 2019
10th May 20197:00 amRNSNotice of Results
25th Apr 20197:00 amRNSUpdate for first half of year ending 31 March 2019
24th Apr 20197:00 amRNSAnnounces two new biopharmaceutical contracts
12th Apr 20197:00 amRNSChange of Adviser
19th Mar 20194:20 pmRNSHolding(s) in Company
18th Mar 201912:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSLate phase clinical study in Huntington's disease
1st Mar 20197:00 amRNSIXICO chosen for new Medical Imaging & AI Centre
7th Feb 20197:00 amRNSAppointment of Chief Financial Officer
11th Dec 20187:00 amRNSDirectorate Change
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.